本次美国天境宣布暂停对CD73单抗Uliledlimab开发的原因是——以便公司能将资源集中在推进核心项目givastomig的开发上。因此，对Uliledlimab的进一步临床投资将被搁置。并未披露是否与Uliledlimab的本身有关。

Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

CD73棋局：天境生物携手赛诺菲突围，I-MAB“以逸待劳”躺赢？ 在市场的凛冬时节，如何顺利完成盈利并上岸，是每一家biotech必须面对的问题，同时 ...

I-Mab has begun the new year with a pipeline pivot, pausing work on an asset that Sanofi bought into last year to focus on ...

I-Mab shifts focus to givastomig, a bispecific antibody for CLDN18.2-positive tumors, following positive early data and ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights to ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights ...